Noticias

Noticias

  • Título: CMS Approves Removal of Device Offset Charge Associated With Pass-Through Payment for Drug-Coated Balloons (DCBs) Under Medicare Hospital Outpatient Prospective Payment System
  • Fecha: 11-06-2015

  • June 11, 2015 — (Statement from Medtronic) — In February, U.S. Centers for Medicare and Medicaid Services (CMS) announced it approved a transitional pass-through payment for the company's IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS). Since then, Medtronic has been leading collaboration with CMS to review policy in an effort to extend patient access to DCB technology, which provides significant improvement to the standard of care for treatment of peripheral arterial disease in the superficial femoral artery (SFA).

    We are excited by their decision to remove the device offset charge. The decision to reimburse the full cost of DCBs will ultimately help to improve patient access to IN.PACT Admiral DCB.

    Recently approved by the U.S. Food and Drug Administration (FDA) on the strength of clinical and economic data from multiple studies, the IN.PACT Admiral DCB offers patients a new therapy option that has demonstrated the best clinical outcomes ever reported (and published in peer reviewed circulation) for this disease state and has been proven to reduce the need for costly repeat procedures that are commonly associated with other available interventional therapies.



  • Fuente: endovascular.es